
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (NERV)
WebsitePrice
Market cap
Next catalystMDD3003 estimated primary-outcome completion: December 2026seltorexant — MDD3003 adjunctive treatment · Study completionSEC filing ↗
Cash

Minerva Neurosciences, Inc.